Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2012

Kong Seogkyoung, Sengupta Sadhak, Tyler Betty, Bais Anthony J, Ma Qiangzhong, Doucette Saryn, Zhou Jinyuan, Sahin Ayguen, Carter Bob S, Brem Henry, Junghans Richard P, Sampath Prakash

Abstract excerpt

PURPOSE: Glioblastoma multiforme (GBM) remains highly incurable, with frequent recurrences after standard therapies of maximal surgical resection, radiation, and chemotherapy. To address the need for new treatments, we have undertaken a chimeric antigen receptor (CAR) "designer T cell" (dTc) immunotherapeutic strategy by exploiting interleukin (IL)13 receptor α-2 (IL13Rα2) as a GBM-selective target. EXPERIMENTAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD28 Antigens
Share to Gene Order

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Immunotherapy, Adoptive

Share to Interleukin-13

Share to Protein Multimerization

Share to Receptors, Antigen, T-Cell

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 22966020
DOI: 10.1158/1078-0432.CCR-12-0319
PMCID: PMC4337849

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.PMID 22966020Read ↗

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in GlioblastomaSemantic proximity Read ↗

Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARsSemantic proximity Read ↗

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive GliomaSemantic proximity Read ↗

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T CellsSemantic proximity Read ↗

Selective IL13Rα2-Targeted Functionality of IL13-Ligand CARs is Enhanced by Inclusion of 4-1BB Co-StimulationSemantic proximity Read ↗

Highly potent novel multi-armoured IL13Ra2 CAR-T subverts the immunosuppressive microenvironment of GlioblastomaSemantic proximity Read ↗

Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma TherapySemantic proximity Read ↗

In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformeSemantic proximity Read ↗

A Bi-Specific T Cell-Engaging Antibody Triggers Protective Immune Memory and Glioma Microenvironment Remodeling in Immune Competent Preclinical ModelsSemantic proximity Read ↗

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.Semantic proximity Read ↗

Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T CellsSemantic proximity Read ↗

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.